← All trials
NCT05279651
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 13, 2022
- Primary completion
- Mar 15, 2025
- Completion date
- Mar 31, 2026
- First posted
- Mar 15, 2022
- Last posted
- Dec 20, 2022
- Enrollment
- 2500
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Jagiellonian UniversityLead sponsor
- Jagiellonian UniversityReponsible party - principal investigator
- McMaster UniversityCollaborator
- Vanderbilt UniversityCollaborator
- Jagiellonian UniversityOfficial
- Jagiellonian UniversitySponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.